×
About 5,847 results

ALLMedicine™ Calcitonin Gene-related Peptide Center

Research & Reviews  2,751 results

CGRP receptor antagonists for migraine - are they also AMY1 receptor antagonists?
https://doi.org/10.1111/bph.15585
British Journal of Pharmacology; Garelja ML, Walker CS et. al.

Jun 2nd, 2021 - The development of several drugs that target the calcitonin gene-related peptide (CGRP) system has been a major breakthrough in the pharmacological management of migraine. These are divided into two major classes: antibodies which bind to the CGRP...

Effects of the prenatal environment on cryptorchidism: A narrative review.
https://doi.org/10.1111/iju.14600
International Journal of Urology : Official Journal of Th... Mitsui T

Jun 2nd, 2021 - Cryptorchidism, the absence of testes from the scrotum, is the most common genital disorder in boys and a risk factor for reduced fertility and testicular cancer. The mechanism responsible for cryptorchidism involves two discrete stages: a transab...

Preventive Migraine Treatment.
https://doi.org/10.1212/CON.0000000000000957 10.1212/WNL.0000000000007856 10.1111/head 10.1177/0333102414547138 10.1038/clpt.2008.203 10.1212/wnl.53.5.988 i10.1023/a:1026119331193 10.1046/j.1468-2982.2002.00386.x 10.1212/01.wnl.0000252808.97649.21 10.1212/WNL.0b013e3182535d20 10.1007/s00228-019-02790-2 10.1111/j.1526-4610.2012.02185.x 10.1007/s11940-019-0557-2 10.1111/head.12987 10.1111/head.12205 10.1159/000491524 10.1007/s11916-019-0823-8 10.1007/s11940-019-0558-1 10.1007/s11940-019-0559-0 10.1186/s10194-019-0974-3 10.1186/s12883-020-01633-3 10.1111/head.13379 10.1177/0333102420946725 10.1177/0333102419894559 10.1111/head.13417 10.1177/0333102419854082 10.1016/S0140-6736(19)32504-8 10.1186/s10194-017-0807-1 10.1186/s10194-018-0923-6 10.1177/0333102419858355 10.1111/head 10.1136/bmj.g1416 10.1212/WNL.0000000000002560 10.1111/head.13843 10.1177/0333102415593088 10.1093/brain/awz052 10.1016/j.ncl.2019.06.001 10.1111/head.13313 10.1212/WNL.0b013e31824d5846 10.1111/jcpt.12548 10.1111/head.13934 10.1111/head.13828 10.1212/WNL.0b013e3182535d0c 10.1111/head.13217 10.1007/s11916-019-0750-8 10.1155/2019/6320163 10.1007/s11916-018-0735-z 10.1002/ana.24534 10.1007/s10194-012-0490-1 10.1177/2515816318759304 10.1212/wnl.55.6.754 10.1136/bmj.j1805 10.1212/WNL.0000000000009473 10.1097/WNO.0000000000000841 10.1136/bmj.c4871 10.1177/0333102411436333 10.1002/14651858.cd001218.pub3 10.1111/head.13069 10.1097/WCO.0000000000000820 10.1212/01.wnl.0000435063.25330.55 10.1093/pm/pnz119 10.1186/s12883-017-0869-3 10.1177/0333102418762525 10.1016/S0140-6736(20)32544-7
Continuum (Minneapolis, Minn.); Burch R

May 28th, 2021 - This article provides an overview of preventive interventions for migraine, including when to start and how to choose a treatment, pharmacologic options (both older oral treatments and new monoclonal antibodies to calcitonin gene-related peptide [...

Matching-adjusted indirect comparisons of oral rimegepant versus placebo, erenumab, and...
https://doi.org/10.1111/head.14128
Headache Popoff E, Johnston K et. al.

May 22nd, 2021 - Rimegepant is an orally administered small-molecule calcitonin gene-related peptide (CGRP) receptor antagonist, with demonstrated efficacy in the acute treatment of migraine. Recent estimates from a single-arm trial (BHV3000-201) have also shown e...

Calcitonin gene-related peptide regulates spinal microglial activation through the hist...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8139106
Journal of Neuroinflammation; An Q, Sun C et. al.

May 22nd, 2021 - Calcitonin gene-related peptide (CGRP) as a mediator of microglial activation at the transcriptional level may facilitate nociceptive signaling. Trimethylation of H3 lysine 27 (H3K27me3) by enhancer of zeste homolog 2 (EZH2) is an epigenetic mark ...

see more →

Guidelines  1 results

European headache federation guideline on the use of monoclonal antibodies acting on th...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6734227
The Journal of Headache and Pain; Sacco S, Bendtsen L et. al.

Jan 17th, 2019 - Monoclonal antibodies acting on the calcitonin gene-related peptide or on its receptor are new drugs to prevent migraine. Four monoclonal antibodies have been developed: one targeting the calcitonin gene-related peptide receptor (erenumab) and thr...

see more →

Drugs  5 results see all →

Clinicaltrials.gov  2,899 results

Botox, CGRP a Dynamic Duo for Migraine?
https://www.medscape.com/viewarticle/952790

Jun 8th, 2021 - OnabotulinumtoxinA alone provides relief from chronic migraine, and addition of anti-calcitonin gene-related peptide (CGRP) antibodies may boost the benefit, according to a large retrospective analysis. The results lend hope that the combination m...

CGRP receptor antagonists for migraine - are they also AMY1 receptor antagonists?
https://doi.org/10.1111/bph.15585
British Journal of Pharmacology; Garelja ML, Walker CS et. al.

Jun 2nd, 2021 - The development of several drugs that target the calcitonin gene-related peptide (CGRP) system has been a major breakthrough in the pharmacological management of migraine. These are divided into two major classes: antibodies which bind to the CGRP...

Effects of the prenatal environment on cryptorchidism: A narrative review.
https://doi.org/10.1111/iju.14600
International Journal of Urology : Official Journal of Th... Mitsui T

Jun 2nd, 2021 - Cryptorchidism, the absence of testes from the scrotum, is the most common genital disorder in boys and a risk factor for reduced fertility and testicular cancer. The mechanism responsible for cryptorchidism involves two discrete stages: a transab...

Preventive Migraine Treatment.
https://doi.org/10.1212/CON.0000000000000957 10.1212/WNL.0000000000007856 10.1111/head 10.1177/0333102414547138 10.1038/clpt.2008.203 10.1212/wnl.53.5.988 i10.1023/a:1026119331193 10.1046/j.1468-2982.2002.00386.x 10.1212/01.wnl.0000252808.97649.21 10.1212/WNL.0b013e3182535d20 10.1007/s00228-019-02790-2 10.1111/j.1526-4610.2012.02185.x 10.1007/s11940-019-0557-2 10.1111/head.12987 10.1111/head.12205 10.1159/000491524 10.1007/s11916-019-0823-8 10.1007/s11940-019-0558-1 10.1007/s11940-019-0559-0 10.1186/s10194-019-0974-3 10.1186/s12883-020-01633-3 10.1111/head.13379 10.1177/0333102420946725 10.1177/0333102419894559 10.1111/head.13417 10.1177/0333102419854082 10.1016/S0140-6736(19)32504-8 10.1186/s10194-017-0807-1 10.1186/s10194-018-0923-6 10.1177/0333102419858355 10.1111/head 10.1136/bmj.g1416 10.1212/WNL.0000000000002560 10.1111/head.13843 10.1177/0333102415593088 10.1093/brain/awz052 10.1016/j.ncl.2019.06.001 10.1111/head.13313 10.1212/WNL.0b013e31824d5846 10.1111/jcpt.12548 10.1111/head.13934 10.1111/head.13828 10.1212/WNL.0b013e3182535d0c 10.1111/head.13217 10.1007/s11916-019-0750-8 10.1155/2019/6320163 10.1007/s11916-018-0735-z 10.1002/ana.24534 10.1007/s10194-012-0490-1 10.1177/2515816318759304 10.1212/wnl.55.6.754 10.1136/bmj.j1805 10.1212/WNL.0000000000009473 10.1097/WNO.0000000000000841 10.1136/bmj.c4871 10.1177/0333102411436333 10.1002/14651858.cd001218.pub3 10.1111/head.13069 10.1097/WCO.0000000000000820 10.1212/01.wnl.0000435063.25330.55 10.1093/pm/pnz119 10.1186/s12883-017-0869-3 10.1177/0333102418762525 10.1016/S0140-6736(20)32544-7
Continuum (Minneapolis, Minn.); Burch R

May 28th, 2021 - This article provides an overview of preventive interventions for migraine, including when to start and how to choose a treatment, pharmacologic options (both older oral treatments and new monoclonal antibodies to calcitonin gene-related peptide [...

Ajovy - fremanezumab-vfrm injection-Teva Pharmaceuticals USA, Inc.
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=98e344ea-5916-4947-b6f2-4a76ccc04b6b

May 27th, 2021 - AJOVY is indicated for the preventive treatment of migraine in adults. AJOVY is a calcitonin gene-related peptide antagonist indicated for the preventive treatment of migraine in adults. (1)

see more →

News  191 results

Botox, CGRP a Dynamic Duo for Migraine?
https://www.medscape.com/viewarticle/952790

Jun 8th, 2021 - OnabotulinumtoxinA alone provides relief from chronic migraine, and addition of anti-calcitonin gene-related peptide (CGRP) antibodies may boost the benefit, according to a large retrospective analysis. The results lend hope that the combination m...

FDA Expands Rimegepant Indication to Include Migraine Prevention
https://www.medscape.com/viewarticle/952073

May 27th, 2021 - The US Food and Drug Administration (FDA) has expanded the indication for rimegepant (Nurtec ODT, Biohaven) to include prevention of migraine in adults. Last year, rimegepant became the first calcitonin gene-related peptide (CGRP) receptor antagon...

Intranasal Third-Generation CGRP Effective for Acute Migraine
https://www.medscape.com/viewarticle/949517

Apr 18th, 2021 - Intranasal zavegepant, a third-generation calcitonin gene-related peptide (CGRP) receptor agonist, is effective and well tolerated in the treatment of acute migraine, new research shows. In a randomized dose-ranging, placebo-controlled, phase 2/3 ...

CGRPs Promising for Prevention of Chronic Cluster Headache
https://www.staging.medscape.com/viewarticle/937760

Sep 20th, 2020 - Treatment with calcitonin gene-related peptide (CGRP) monoclonal antibodies may reduce the frequency of chronic cluster headache (CCH) attacks in patients with an inadequate response to other preventive medications, new research shows. In findings...

CGRPs Promising for Prevention of Chronic Cluster Headache
https://www.medscape.com/viewarticle/937760

Sep 20th, 2020 - Treatment with calcitonin gene-related peptide (CGRP) monoclonal antibodies may reduce the frequency of chronic cluster headache (CCH) attacks in patients with an inadequate response to other preventive medications, new research shows. In findings...

see more →